Open AccessA stroma‐related lncRNA panel for predicting recurrence and adjuvant chemotherapy benefit in patients with early‐stage colon cancer
Author(s) -
Zhou Rui,
Sun Huiying,
Zheng Siting,
Zhang Jingwen,
Zeng Dongqiang,
Wu Jianhua,
Huang Zhenhua,
Rong Xiaoxiang,
Bin Jianping,
Liao Yulin,
Shi Min,
Liao Wangjun
Publication year - 2020
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.14999
Subject(s) - oncology , colorectal cancer , medicine , stromal cell , stage (stratigraphy) , chemotherapy , proportional hazards model , adjuvant chemotherapy , univariate analysis , competing endogenous rna , adjuvant , univariate , adjuvant therapy , cancer , multivariate analysis , biology , long non coding rna , breast cancer , multivariate statistics , rna , gene , biochemistry , statistics , mathematics , paleontology
The heterogeneity in prognoses and chemotherapeutic responses of colon cancer patients with similar clinical features emphasized the necessity for new biomarkers that help to improve the survival prediction and tailor therapies more rationally and precisely. In the present study, we established a s troma‐related l ncRNA s ignature (SLS) based on 52 lncRNAs to comprehensively predict clinical outcome. The SLS model could not only distinguish patients with different recurrence and mortality risks through univariate analysis, but also served as an independent factor for relapse‐free and overall survival. Compared with the conventionally used TNM stage system, the SLS model clearly possessed higher predictive accuracy. Moreover, the SLS model also effectively screened chemotherapy‐responsive patients, as only patients in the low‐SLS group could benefit from adjuvant chemotherapy. The following cell infiltration and competing endogenous RNA (ceRNA) network functional analyses further confirmed the association between the SLS model and stromal activation‐related biological processes. Additionally, this study also identified three phenotypically distinct colon cancer subtypes that varied in clinical outcome and chemotherapy benefits. In conclusion, our SLS model may be a significant determinant of survival and chemotherapeutic decision‐making in colon cancer and may have a strong clinical transformation value.